Back to search

Peptide record

TPDB10838

A12L/A20L Antibacterial Anticancer Antifungal Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10838
A12L/A20L
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KWKSFLKTFKSLKKTVLHTLLKAISS
Physicochemical Analysis
C145H242N36O34
RNDCEQGMPY
K
3033.74
11.29
8
0
11
+7
1.51
-0.062
105.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
181.29
7
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
5
L
7
K
0
M
2
F
0
P
4
S
3
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 5 K: 7 M: 0 F: 2 P: 0 S: 4 T: 3 W: 1 Y: 0 V: 1
Chemical Descriptors
26
C145H242N36O34
3033.74
11.29
+7
1.51
-0.062
Free
L
Linear
Free
Anticancer
PeptideV13K
Evidence Records 13 records
Evidence 1 Activity

Activity

IC50
IC50=9.7 µMo/L
Anticancer
9.7 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=8.7 µMo/L
Anticancer
8.7 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 3 Activity

Activity

IC50
IC50=6.2 µMo/L
Anticancer
6.2 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 4 Activity

Activity

IC50
IC50=4.3 µMo/L
Anticancer
4.3 µM

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 5 Activity

Activity

IC50
IC50=6.4 µMo/L
Anticancer
6.4 µM

Target

Rhabdomyosarcoma Cancer
RD
Muscle

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 6 Activity

Activity

IC50
IC50=4.1 µMo/L
Anticancer
4.1 µM

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 7 Activity

Activity

IC50
IC50=4.4 µMo/L
Anticancer
4.4 µM

Target

Skin Cancer
B-16
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 8 Activity

Activity

IC50
IC50=2 µMo/L
Anticancer
2 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 9 Activity

Activity

<5% Hemolysis
Toxicity
4 µM
Hemolytic Cytotoxic
<5% Hemolysis | 4 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Specificity and mechanism of action of alpha-helical membrane-active peptides interacting with model and biological membranes by single-molecule force spectroscopy. | Sci Rep | 2016
Evidence 10 Activity

Activity

50% Cell death
Toxicity
7.55 µM
Cytotoxic
50% Cell death | 7.55 | µM | target cell: Mouse fibroblasts 3T3-L1

Target

Mouse fibroblasts 3T3-L1

Source & Reference

NA
DBAASP
Specificity and mechanism of action of alpha-helical membrane-active peptides interacting with model and biological membranes by single-molecule force spectroscopy. | Sci Rep | 2016
Evidence 11 Activity

Activity

MHC
Toxicity
10.40
Hemolytic
Hemolytic_activity: [Ref.22837667]MHC=10.40±0.08 µmol/L against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Mol Sci. 2012 13(6):6849-62. doi: 10.3390/ijms13066849.
Evidence 12 Activity

Activity

MHC
Toxicity
20.81
Hemolytic
Hemolytic_activity: [Ref.22837667]MHC=20.81±0.03 µmol/L against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Mol Sci. 2012 13(6):6849-62. doi: 10.3390/ijms13066849.
Evidence 13 Activity

Activity

MHC
Toxicity
20.81
Hemolytic
Hemolytic_activity: [Ref.22837667]MHC=20.81±0.13 µmol/L against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Mol Sci. 2012 13(6):6849-62. doi: 10.3390/ijms13066849.